Taiwan · Delayed Price · Currency is TWD Oneness Biotech Statistics
Total Valuation
Oneness Biotech has a market cap or net worth of TWD 22.51 billion. The enterprise value is 17.57 billion.
| Market Cap | 22.51B |
| Enterprise Value | 17.57B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oneness Biotech has 479.38 million shares outstanding. The number of shares has decreased by -0.68% in one year.
| Current Share Class | 479.38M |
| Shares Outstanding | 479.38M |
| Shares Change (YoY) | -0.68% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 9.38% |
| Owned by Institutions (%) | 4.46% |
| Float | 326.66M |
Valuation Ratios
The trailing PE ratio is 370.08.
| PE Ratio | 370.08 |
| Forward PE | n/a |
| PS Ratio | 146.35 |
| PB Ratio | 2.17 |
| P/TBV Ratio | 2.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 288.95 |
| EV / Sales | 114.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 37.31, with a Debt / Equity ratio of 0.03.
| Current Ratio | 37.31 |
| Quick Ratio | 36.36 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.85 |
| Interest Coverage | -94.19 |
Financial Efficiency
Return on equity (ROE) is 0.62% and return on invested capital (ROIC) is -12.48%.
| Return on Equity (ROE) | 0.62% |
| Return on Assets (ROA) | -4.27% |
| Return on Invested Capital (ROIC) | -12.48% |
| Return on Capital Employed (ROCE) | -7.09% |
| Weighted Average Cost of Capital (WACC) | 8.18% |
| Revenue Per Employee | 3.58M |
| Profits Per Employee | 1.41M |
| Employee Count | 43 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.89 |
Taxes
In the past 12 months, Oneness Biotech has paid 13.56 million in taxes.
| Income Tax | 13.56M |
| Effective Tax Rate | 16.93% |
Stock Price Statistics
The stock price has decreased by -33.78% in the last 52 weeks. The beta is 0.73, so Oneness Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -33.78% |
| 50-Day Moving Average | 48.55 |
| 200-Day Moving Average | 55.57 |
| Relative Strength Index (RSI) | 48.35 |
| Average Volume (20 Days) | 1,897,628 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oneness Biotech had revenue of TWD 153.78 million and earned 60.82 million in profits. Earnings per share was 0.13.
| Revenue | 153.78M |
| Gross Profit | 56.74M |
| Operating Income | -787.70M |
| Pretax Income | 80.10M |
| Net Income | 60.82M |
| EBITDA | -509.14M |
| EBIT | -787.70M |
| Earnings Per Share (EPS) | 0.13 |
Balance Sheet
The company has 5.43 billion in cash and 352.21 million in debt, with a net cash position of 5.08 billion or 10.60 per share.
| Cash & Cash Equivalents | 5.43B |
| Total Debt | 352.21M |
| Net Cash | 5.08B |
| Net Cash Per Share | 10.60 |
| Equity (Book Value) | 10.39B |
| Book Value Per Share | 21.34 |
| Working Capital | 5.62B |
Cash Flow
In the last 12 months, operating cash flow was -174.55 million and capital expenditures -15.47 million, giving a free cash flow of -190.02 million.
| Operating Cash Flow | -174.55M |
| Capital Expenditures | -15.47M |
| Depreciation & Amortization | 278.56M |
| Net Borrowing | -43.30M |
| Free Cash Flow | -190.02M |
| FCF Per Share | -0.40 |
Margins
Gross margin is 36.89%, with operating and profit margins of -512.21% and 39.55%.
| Gross Margin | 36.89% |
| Operating Margin | -512.21% |
| Pretax Margin | 52.09% |
| Profit Margin | 39.55% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oneness Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.68% |
| Shareholder Yield | 0.68% |
| Earnings Yield | 0.27% |
| FCF Yield | -0.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2024. It was a forward split with a ratio of 1.049967976.
| Last Split Date | Jul 26, 2024 |
| Split Type | Forward |
| Split Ratio | 1.049967976 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |